Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
SWOG S1815
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
- NCT03768414 ↗
- Completed
- SWOG Cancer Research Network
- Standard
We haven't built an HCP commentary report on SWOG S1815 (nab-paclitaxel in newly diagnosed advanced biliary tract cancers) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SWOG S1815 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 14 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Stage III Distal Bile Duct Cancer AJCC v8; Stage III Gallbladder Cancer AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Distal Bile Duct Cancer AJCC v8; Stage IIIA Gallbladder Cancer AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Distal Bile Duct Cancer AJCC v8; Stage IIIB Gallbladder Cancer AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Gallbladder Cancer AJCC v8; Stage IVB Gallbladder Cancer AJCC v8; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
- Interventions
- Cisplatin; Gemcitabine Hydrochloride; Nab-paclitaxel
- Arms
- Arm I (nab-paclitaxel, cisplatin, gemcitabine hydrochloride) · Experimental
- Arm II (cisplatin, gemcitabine hydrochloride) · Experimental
- Enrollment
- 452
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- SWOG Cancer Research Network with National Cancer Institute (NCI)
- Start
- Feb 7, 2019
- Primary completion
- Oct 4, 2023
- Results posted
- Yes
- Registry record
- NCT03768414 · updated Jan 12, 2026
Publications
linked from the registry- Shroff RT, King G, Colby S, Scott AJ, Borad MJ, Goff L, Matin K, Mahipal A, Kalyan A, Javle MM, El Dika I, Tan B, Cheema P, Patel A, Iyer R, Kelley RK, Thumar J, El-Khoueiry A, Guthrie KA, Chiorean EG, Hochster H, Philip PA. SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. J Clin Oncol. 2025 Feb 10;43(5):536-544. doi: 10.1200/JCO-24-01383. Epub 2024 Dec 13. PubMed 39671534